Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
about
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknownHSV-2: in pursuit of a vaccineDevelopment of a guinea pig immune response-related microarray and its use to define the host response following Mycobacterium bovis BCG vaccinationLaser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal Ganglia at the single-cell level.Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigsCurrent status and prospects for development of an HSV vaccineRationalizing the development of live attenuated virus vaccinesA gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in the lung but fails to vaccinate against a wild-type virus challenge.High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivoImmunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital modelRecombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 diseaseEvidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach.Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursorsHerpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigsAbility of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virusCross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine.siRNA-based topical microbicides targeting sexually transmitted infections.Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.Rates of reactivation of latent herpes simplex virus from mouse trigeminal ganglia ex vivo correlate directly with viral load and inversely with number of infiltrating CD8+ T cells.Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease.Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in gangliaProtection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes.The cycle of human herpes simplex virus infection: virus transport and immune control.The challenge of developing a herpes simplex virus 2 vaccine.An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention.A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeuticsSerological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay.
P2860
Q21296712-D0DD91C6-6832-478A-8010-75D5ACBB1ECEQ22306291-4FD30701-E4B1-455D-BC06-3281318F8F88Q30231394-FA4012B7-4735-4675-8B8B-BB18DCCCD044Q33226129-15594DE4-4D18-4BDD-B160-258EE6372D18Q33595097-E066578C-78B0-4E1D-AF22-5B09D2442363Q33724497-78CAA074-D77F-4438-9AE4-F712E226B17EQ33825931-6BAC860C-9FCF-4B83-BCFF-0515C807CE2EQ33931016-D3922620-3A6C-4E50-A0B8-3BE59DAF96A3Q34119676-AF03396C-4110-4228-934B-9739AD162E0FQ34302056-3640DAA1-FC66-46E6-8668-38921892847AQ34331569-432271F1-4916-4791-B0AA-29966B3A2FEBQ34447379-A8FE5686-8223-4923-BBC3-03B24D7B6FB8Q34647625-2119DFB3-61D3-467E-9632-A522C8AE2891Q34742583-F02DC985-8C84-4E89-8B16-68B936195DF7Q34834264-C6CC7AC4-17B7-46FE-8D6F-ECC73B1858C5Q35058245-D84287F3-8E13-4342-BF76-5EBB2DCF964EQ35061783-F8E77330-0D65-47FA-A63E-B887A9E621C1Q35111489-99C31CB0-F746-4BC1-A552-114EEC0A1471Q35156674-CB7E484B-4343-4BD4-B277-E39E031E133BQ35173777-32494AB8-544D-4CD4-B687-7934C145ABF7Q35249684-567B269D-5673-4220-830A-E9EDB5094660Q35675044-BBDC7C2C-CC0B-44FE-B2B8-2E16090E8D06Q35699002-152D0433-D113-498C-B39D-C48B91E9FCDAQ35766254-81EC9C5D-D7EE-46F6-81AE-F1D01C21FE45Q35867958-D9B931D2-0AA2-47F5-ABB0-A03B9E267BCAQ35947667-5B1C8425-03D0-4FDE-881D-9880A4539368Q36080869-C4F099E9-7AB0-4BA7-97CC-1664BFB8A4F1Q36176893-3CD8453C-6B3E-4C3A-8143-47D60E7F7F57Q36520832-B4443987-A13E-499B-9BB0-CD28739BB92CQ36528488-62E8DED3-D3A3-4DE7-9C05-EE6A05DB3E6FQ36553837-AE1773F8-755D-440C-BF48-49ED2B686DF0Q36570266-66817F62-E579-4B90-82A5-164668F75BBBQ36572093-EA1508E6-EAF1-41DF-8F95-807915FE89DAQ36671106-A3C523BE-DB36-4DBB-8B56-48D86DA9B993Q36759693-7A86475B-B3F4-49EE-A377-D21F57223B5CQ36765590-A149C131-8AC3-4038-B094-05A9870FC441Q36845870-F575B7FA-E04C-4388-BC1B-34AA39E93751Q36931089-2219B761-26D0-4AE8-B3F6-7B9194A03A8AQ36977847-1CBA51B9-D9B6-4391-BCD8-39082D1F4A4BQ37116538-141DF15A-3A63-4CFA-8ADD-6D98D1BC3D99
P2860
Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparative efficacy and immun ...... tions in mice and guinea pigs.
@en
Comparative efficacy and immun ...... tions in mice and guinea pigs.
@nl
type
label
Comparative efficacy and immun ...... tions in mice and guinea pigs.
@en
Comparative efficacy and immun ...... tions in mice and guinea pigs.
@nl
prefLabel
Comparative efficacy and immun ...... tions in mice and guinea pigs.
@en
Comparative efficacy and immun ...... tions in mice and guinea pigs.
@nl
P2093
P2860
P1433
P1476
Comparative efficacy and immun ...... tions in mice and guinea pigs.
@en
P2093
David M Knipe
Jeffrey I Cohen
Kening Wang
Lesley Pesnicak
Sarat K Dalai
Stephen E Straus
Yo Hoshino
P2860
P304
P356
10.1128/JVI.79.1.410-418.2005
P407
P577
2005-01-01T00:00:00Z